Sumeet Singh Mitter, MD, MSc
@SumeetMitter
Followers
1K
Following
13K
Media
83
Statuses
822
Director Infiltrative & Restrictive Cardiomyopathies, Clinical Trialist @ISHVnews | @DOMSinaiNYC & @NMCardioVasc alum | Coffee Lover | Sikh/Punjabi-American
Falls Church, VA
Joined February 2012
RT @ISHVnews: Bringing @ISHVnews expertise.to 3CT. @ShashankSinhaMD-Serial Shock Assessment.@cmrosner-Biomarkers/Patient Empowerment.@coco….
0
3
0
RT @hfcollaboratory: #3CT in action! Infinitely proud of our #HFC members #clinicaltrial #heartfailure #heartfailurecollaboratory
https://t….
0
1
0
RT @JReinerMD: When Cassidy practiced medicine he fought to vaccinate kids against Hep B. But in a desperate attempt to be re-elected to th….
0
2K
0
RT @Ron_Witteles: Excited to have participated in this #Delphi study for the management of 🫀#sarcoidosis, just published in @JACCJournals.….
0
25
0
RT @MasriAhmadMD: With all the recent news about ATTR therapies, it is good to remember that it is not a benign disease. Outcomes have trem….
0
16
0
RT @MasriAhmadMD: Great to see this paper out in @JACCJournals. Establishing the role of transthyretin (prealbumin) as a surrogate of treat….
0
13
0
RT @Ed_Alania: 🔴 Early Increase in Serum TTR by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy @JACCJour….
0
21
0
RT @MasriAhmadMD: Critical data - while bone scintigraphy has resulted in a massive improvement in our diagnostic abilities in transthyreti….
0
15
0
RT @MasriAhmadMD: Further analysis from ATTRIBUTE-CM utilizing different NTproBNP cut offs as a marker of disease severity, and evaluating….
0
2
0
RT @MasriAhmadMD: A further dive into the primary efficacy endpoint in ATTRibute-CM .#ACC25 #CardioTwitter .#MEDIQACC25 .
0
7
0
RT @InovaCVfellows: So glad to have another medication for our patients with TTR amyloid. @SumeetMitter.
0
1
0
RT @Ron_Witteles: A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B tr….
0
49
0
Thank you to @robmentz and @dranulala for the opportunity to address the current state of the field.
0
0
2
As ❤ month closes, let's not lose sight of recent advances in TTR Amyloid - my thoughts in @JCardFail w/ @PalomaRemior on tafamidis in the real world and newer therapies entering the arena. Will the data support tafamidis' 1st mover advantage?.
2
17
41
RT @GarimaVSharmaMD: Guidance from the best team with tremendous outcomes in Critical Care and HF. Fantastic work in @CircAHA on this @AHAS….
0
4
0
RT @DrScottHadland: Alarmingly, RFK Jr has been confirmed as HHS Secretary. The lone Republican vote against him? Senator Mitch McConnell,….
0
141
0
RT @GarimaVSharmaMD: Amazing @GoRedForWomen @AHAScience day at @ISHVnews with the best colleagues in business @InovaCVfellows @InovaHealth….
0
9
0
RT @ISHVnews: In-depth examination of role of Tafamidis in treatment of ATTR-CM by @SumeetMitter, Remior-Perez in editorial accompanying @….
0
3
0